IL-9R Antibody

Ucma/GRP−/− mVSMCs show increased expression of osteo/chondrogenic markers. Cells were treated with control (CM) or osteogenic medium (OM, with 2.6 mM phosphate) for 12 days. Panels (A–D) qPCR analysis of osteo/chondrogenic gene expression, n = 4–7. Statistical significance was assessed using t-test (Osteocalcin) or ANOVA (E) Western blotting analysis of osteo/chondrogenic markers. Both WT and KO cells were treated with OM. Figure shows full western blots obtained by cutting of a full-sized membrane prior to antibody incubations. Numbers in the middle show molecular weights of the protein standard. Numbers on the right show the expected molecular weights of the proteins. Panels F–I quantification of western blotting results from panel E, n = 3. Statistical significance was assessed using t-test. All graphs show mean + SD. *p between 0.05–0.01, **p between 0.001–0.01. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/29563538), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: WB
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

IL-9R Antibody Summary

• Immunogen: S. frugiperda insect ovarian cell line Sf 21-derived recombinant human IL-9 R
  Val40-Pro270
  Accession # Q01113
• Specificity: Detects human IL-9 R in direct ELISAs and Western blots. In direct ELISAs, approximately 15% cross‑reactivity with recombinant human (rh) IL-2 sR gamma , rhIL-5 sR alpha , and rhIL-6 sR is observed and 10% cross-reactivity with rhIL‑2 sR beta is observed and 5% cross‑reactivity with rhIL‑1 sRII, rhIL-4 sR, and rhIL-10 sR is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: IL9R
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-9R Antibody

• CD129 antigen
• CD129
• IL-9 R
• IL-9 receptor
• IL9R
• IL-9R
• interleukin 9 receptor
• interleukin-9 receptor

Background

The specific high affinity functional IL-9 receptor complex consists of a ligand-specific IL-9 R( alpha ) type I transmembrane subunit and the common gamma chain that is shared with the receptors for IL-2, IL-4, IL-7 and IL-15. Both the IL-9 R subunit and the common gamma chain are members of the hematopoietin receptor superfamily. Human and mouse IL-9 receptors share 53% amino acid sequence identity, and contain 468 and 533 amino acids, respectively. As a result of alternative splicing, cDNA clones encoding isoforms of IL-9 R, including a putative soluble form, have also been identified. Cells known to express IL-9 R include T cells, neutrophils, mast cells and macrophages.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IL-9R Antibody (AF290)(1)

Publication using AF290

• BA Willems, M Furmanik, MMJ Caron, MLL Chatrou, DHM Kusters, TJM Welting, M Stock, MS Rafael, CSB Viegas, DC Simes, C Vermeer, CPM Reutelings, LJ Schurgers Ucma/GRP inhibits phosphate-induced vascular smooth muscle cell calcification via SMAD-dependent BMP signalling Sci Rep, 2018-03-21;8(1):4961. 3/21/2018 [PMID: 29563538]

Bioinformatics

• Gene Symbol: IL9R
• Uniprot:
  • Q01113()